Survey of symptoms following COVID-19 vaccination in India

  1. Rajeev Jayadevan
  2. Ramesh Shenoy
  3. Anithadevi TS

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

COVID-19 vaccines have been rolled out recently in several parts of the world. Although the protective efficacy is frequently discussed, little is known about the real-world post-vaccination experience outside of clinical trial conditions. Knowledge about what to expect after vaccination will help educate the public, dispel misinformation and reduce vaccine hesitancy.

Aim

  • To assess the immediate response to the first dose of COVID-19 vaccine.

  • To study the spectrum of post-vaccination symptom profile for individual vaccines.

    • Methods

    A cross-sectional online survey was done which included questions pertaining to the immediate post vaccination experience in India.

    Results

    A total of 5396 people responded to the survey over a one-week period from 29 January to 4 February. Overall, 65.9 % of respondents reported at least one post-vaccination symptom. Tiredness (45%), myalgia (44%), fever (34%), headache (28%), local pain at injection site (27%), joint pain (12%), nausea (8%) and diarrhea (3%) were the most prevalent symptoms. The chance of having symptoms decreased with advancing age. The frequency of symptoms was 81% (3rd decade or 20-29 years), 80% (4th decade or 30-39 years), 68% (5th decade), 58% (6th decade), 45% (7th decade), 34% (8th decade) and 7% (9th decade, 80-90 years). Post-vaccination symptoms were more likely to be reported by women (74.7%) compared to men (58.6%) (p < 0.001). Among those who reported symptoms, 79% noticed them within the first 12 hours. 472 out of 5396 (8.7%) reported past history of COVID-19. Their symptom profile was not different to those who did not have a past history.

    Conclusions

    Two-thirds of healthcare professionals who completed the survey reported mild and short-lived post-vaccination symptoms. Tiredness, myalgia and fever were most commonly reported. These symptoms were consistent with an immune response commonly associated with vaccines, and correlated with the findings from previously published phase 2/3 trials. In 90% cases, the symptoms were either milder than expected or meeting the expectation of the vaccine recipient. No serious events were reported. Symptoms were more common among younger individuals. There was no difference in symptoms among those who had a past history of COVID-19.

    Article activity feed

    1. ScreenIT

      SciScore for 10.1101/2021.02.08.21251366: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      Ethicsnot detected.
      Sex as a biological variablenot detected.
      Randomizationnot detected.
      Blindingnot detected.
      Power Analysisnot detected.

      Table 2: Resources

      Software and Algorithms
      SentencesResources
      All the data were entered in Microsoft excel and analyzed using SPSS version 20.00.
      Microsoft excel
      suggested: (Microsoft Excel, RRID:SCR_016137)
      SPSS
      suggested: (SPSS, RRID:SCR_002865)

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.

      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

      Results from JetFighter: We did not find any issues relating to colormaps.

      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    2. Version published to 10.1101/2021.02.08.21251366 on medRxiv